{"id":1068312,"date":"2023-03-31T00:42:40","date_gmt":"2023-03-31T04:42:40","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/hutchmed-completes-rolling-submission-of-nda-to-u-s-fda-for-fruquintinib-for-the-treatment-of-refractory-metastatic-colorectal-cancer\/"},"modified":"2024-08-18T11:45:43","modified_gmt":"2024-08-18T15:45:43","slug":"hutchmed-completes-rolling-submission-of-nda-to-u-s-fda-for-fruquintinib-for-the-treatment-of-refractory-metastatic-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/hutchmed-completes-rolling-submission-of-nda-to-u-s-fda-for-fruquintinib-for-the-treatment-of-refractory-metastatic-colorectal-cancer.php","title":{"rendered":"HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer"},"content":{"rendered":"<p><![CDATA[\u2014 NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China \u2014]]><\/p>\n<p>Read more:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2023\/03\/31\/2638308\/0\/en\/HUTCHMED-Completes-Rolling-Submission-of-NDA-to-U-S-FDA-for-Fruquintinib-for-the-Treatment-of-Refractory-Metastatic-Colorectal-Cancer.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer\">HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read more: HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/hutchmed-completes-rolling-submission-of-nda-to-u-s-fda-for-fruquintinib-for-the-treatment-of-refractory-metastatic-colorectal-cancer.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068312","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068312"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068312"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068312\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}